Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren's): Single-center experience of 160 cases

Onkologie

Volumn 34, Issue 12, 2011, Pages 682-686

  Hass, Holger G ^a   Smith, Ute ^b   Jäger, Christina ^c   Schäffer, Michael ^c   Wellhäußer, Ulrich ^c   Hehr, Thomas ^c   Markmann, Hans Ulrich ^c   Nehls, Oliver ^d   Denzlinger, Claudio ^c  

^a Department of Internal Oncology and Rehabilitation   (Germany)

^b Onkologischer Schwerpunkt Stuttgart   (Germany)

^c MARIENHOSPITAL STUTTGART   (Germany)

^d Hospital Bad Cannstatt   (Germany)

Author keywords

Gastric cancer; Lauren's classification; Signet ring cell carcinoma

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; DIFFUSE GASTRIC CANCER; DIFFUSION GASTRIC CANCER; DISEASE SEVERITY; FEMALE; GASTRECTOMY BILLROTH II; HISTOLOGY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SIGNET RING CARCINOMA; SIGNET RING CELL CARCINOMA OF THE STOMACH; STOMACH CANCER; STOMACH CARCINOMA; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR RECURRENCE;

AGED; CARCINOMA, SIGNET RING CELL; FEMALE; GERMANY; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 83755205895     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000334545     Document Type: Article

References (21)

1. Purcell RH, Bray F, Parkin DM, Pisani P (eds): Gobocan 2000: Cancer Incidence and Mortality Worldwide (IARC Cancer Bases No. 5). Lyon, IARC Press, 2001.
2. Hundahl SA, Phillips JL, Menck HR: The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth edition American Joint Committee on cancer staging, proximal disease, and the 'different disease' hypothesis. Cancer 2000;88:921-932. (Pubitemid 30091113)
3. Lauren P: Histogenesis of intestinal and diffuse types of gastric carcinoma. Scand J Gastroenterol Suppl 1991;180:160-164.
4. Sierra A, Regueira FM, Hernandez-Lizoain JL, Pardo F, Martínez-Gonzalez MA, A-Cienfuegos J: Role of the extended lymphadenectomy in gastric cancer surgery: experience in a single institution. Ann Surg Oncol 2003;10:219-226. (Pubitemid 40486953)
5. Zheng HC, Li XH, Hara T, Masuda S, Yang XH, Guan YF, Takano Y: Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch 2008;452:525-534.
6. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002;420:860-867. (Pubitemid 36019639)
7. Ochiachi A, Yamauchi Y, Hirohashi S: p53 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia. Int J Cancer 1996;69:28-33. (Pubitemid 26083267)
8. Farinat F, Cardin R, Cassaro M, Bortolami M, Nitti D, Tieppo C, Zaninotto G, Rugge M: Helicobacter pylori, inflammation, oxidative damage and gastric cancer: a morphological, biological and molecular pathway. Eur J Cancer Prev 2008;17:195-200. (Pubitemid 351549658)
9. Lau M, Le A, El-Serag HB: Noncardia gastric adenoma remains an important and deadly cancer in the United States: secular trends in incidence and survival. Am J Gastroenterol 2006;101:2485.
10. Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J: Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med 2005;128:765-770.
11. Borch K, Jönsson B, Tarpila E, Franzén T, Berglund J, Kullman E, Franzén L: Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. Br J Surg 2000;87:618-626. (Pubitemid 30261099)
12. Tian MM, Zhao AL, Li ZW, Li JY: Phenotypic classification of gastric signet ring cell carcinoma and its relationship with clinicopathologic parameters and prognosis. World J Gastroenterol 2007; 13:3189-3198.
13. Theuer CP, Nastanski F, Brewster WR, Butler JA, Anton-Culver H: Signet ring cell histology is associated with unique clinical features but does not affect gastric cancer survival. Am Surg 1999;65: 915-921. (Pubitemid 29471313)
14. Kim DY, Park YK, Joo JK, Ryu SY, Kim YJ, Kim SK, Lee JH: Clinicopathological characteristics of signet ring cell carcinoma of the stomach. ANZ J Surg 2004;74:1060-1064. (Pubitemid 40006990)
15. Hyung WJ, Noh SH, Lee JH, Huh JJ, Lah KH, Choi SH, Min JS: Early gastric carcinoma with signet ring cell histology. Cancer 2002;94:78-83. (Pubitemid 34049044)
16. Kim HS, Yi SY, Jun HJ, Lee J, Lee J, Park JO, Park YS, Jang J, Kim HJ, Ko Y, Lim HY, Kang WK: Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology 2007;73:192-197. (Pubitemid 351630049)
17. Li C, Kim S, Lai JF, Hyung WJ, Choi WH, Choi SH, Noh SH: Advanced gastric carcinoma with signet ring cell histology. Oncology 2007;72:64-68. (Pubitemid 350249131)
18. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; MAGIC trial participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
19. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW: Paclitaxel-based chemotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005;23:1237-1244. (Pubitemid 46202281)
20. Jansen EP, Boot H, Dubbelman R, Verheij M, Cats A: Postoperative chemoradiotherapy in gastric cancer-a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy. Ann Oncol 2010;21: 530-534.
21. Field K, Michael M, Leong T: Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008;68: 299-317. (Pubitemid 351227347)